Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYOBLOC for pediatric chronic sialorrhea
NCT05097079Phase 3Withdrawn
- Sponsor
- MDD US Operations
- Start
- Nov 2021
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of botulinum toxin type b in sialorrhea, sponsored by MDD US Operations. Planned start Nov 2021; status: withdrawn.
02
Drugs
botulinum toxin type b
03
Conditions
sialorrhea
Beyond the preview
Go deeper on NCT05097079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097079.